Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
88.08
+4.34 (5.18%)
At close: Feb 21, 2025, 4:00 PM
88.01
-0.07 (-0.08%)
After-hours: Feb 21, 2025, 7:32 PM EST
Novo Nordisk Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Novo Nordisk stock have an average target of 141.67, with a low estimate of 105 and a high estimate of 160. The average target predicts an increase of 60.84% from the current stock price of 88.08.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 23, 2024.
Analyst Ratings
The average analyst rating for Novo Nordisk stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 2 |
| Buy | 4 | 4 | 4 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Sell → Strong Buy Upgrades n/a | Strong Sell → Strong Buy | Upgrades | n/a | n/a | Jan 8, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $156 → $105 | Buy | Maintains | $156 → $105 | +19.21% | Dec 23, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $160 | Buy | Reiterates | $160 | +81.65% | Nov 6, 2024 |
| BMO Capital | BMO Capital | Buy Maintains $160 → $156 | Buy | Maintains | $160 → $156 | +77.11% | Oct 17, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $160 | Buy | Reiterates | $160 | +81.65% | Oct 10, 2024 |
Financial Forecast
Revenue This Year
354.17B
from 290.40B
Increased by 21.96%
Revenue Next Year
414.82B
from 354.17B
Increased by 17.13%
EPS This Year
27.82
from 22.63
Increased by 22.93%
EPS Next Year
33.75
from 27.82
Increased by 21.31%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 380.3B | 479.4B | 571.0B | ||
| Avg | 354.2B | 414.8B | 457.6B | ||
| Low | 324.5B | 367.3B | 388.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 30.9% | 35.4% | 37.7% | ||
| Avg | 22.0% | 17.1% | 10.3% | ||
| Low | 11.7% | 3.7% | -6.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 32.30 | 40.53 | 42.96 | ||
| Avg | 27.82 | 33.75 | 36.37 | ||
| Low | 24.74 | 28.49 | 32.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 42.7% | 45.7% | 27.3% | ||
| Avg | 22.9% | 21.3% | 7.8% | ||
| Low | 9.3% | 2.4% | -5.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.